Sunshine Biopharma Inc. SBFM
Sunshine Biopharma Inc. statistics & valuation
Market cap$4.6M
P / S0.1×
P / B0.2×
Net margin-16.5%
Return on equity-25.9%
FCF margin-15.2%
Return on capital-26.3%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 33.8% | 30.6% | 34.6% | 39.0% | 48.4% | 63.8% | 47.7% | — | — | — |
| Operating margin | -17.2% | -16.7% | -19.9% | -621.3% | -1068.2% | -807.8% | -3037.9% | — | — | — |
| Net margin | -16.5% | -14.7% | -18.7% | -615.4% | -5444.4% | -3898.7% | -7860.9% | — | — | — |
| FCF margin | -15.2% | -40.7% | -36.8% | -125.2% | -800.8% | -922.1% | -2351.5% | — | — | — |
| Return on assets | -19.9% | -16.8% | -16.5% | -91.5% | -564.6% | -266.3% | -1691.7% | -188.1% | -404.0% | -5429.3% |
| Return on equity | -25.9% | -21.8% | -21.2% | -123.7% | -5875.6% | 291.6% | 225.8% | 3867.3% | 181.4% | 1667.5% |
| Debt / equity | — | — | — | — | — | -0.99× | — | — | — | — |
| Current ratio | 4.17 | 4.11 | 4.48 | 3.94 | 24.07 | 0.98 | 0.08 | 1.21 | 0.16 | 0.21 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.